(MYGN) Myriad Genetics - Overview

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US62855J1043

Stock:

Total Rating 16

Risk 39

Buy Signal -1.11

Diagnostics & Research -12.3
Biotechnology +0.8

Market Cap: 446m
Avg Trading Vol: 5.09M USD

ATR: 7.40%
Peers RS (IBD): 4.50

Risk 5d forecast
Volatility	57.2%
Relative Tail Risk	-12.8%

Reward TTM
Sharpe Ratio	-0.61
Alpha	-85.59

Character TTM
Beta	1.691
Beta Downside	0.338

Drawdowns 3y
Max DD	86.57%
CAGR/Max DD	-0.49

EPS (Earnings per Share)

EPS CAGR: 6.37%
EPS Trend: 18.0%

Last SUE: 0.48
Qual. Beats: 0

Revenue

Rev. CAGR: 6.63%
Rev. Trend: 86.2%

Last SUE: 0.36
Qual. Beats: 0

Description: MYGN Myriad Genetics

Myriad Genetics, Inc., a molecular diagnostic testing and precision medicine company, develops and provides molecular tests. The company offers molecular diagnostic tests for oncology, women's health, and pharmacogenomics. It also provides MyRisk Hereditary Cancer test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic test, a DNA sequencing test to help determine the therapy for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. In addition, the company offers Prolaris Prostate Cancer Prognostic test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor Molecular Profile test, a genomic profiling test; Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus; Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek Early Gender DNA test, a non-invasive blood test that predicts the gender of a fetus; and GeneSight Psychotropic Mental Health Medication test, a DNA genotyping test to aid psychotropic drug selection for depression, anxiety, attention-deficit/hyperactivity disorder, and other mental health conditions. It has a license collaboration with Illumina, Inc.; Memorial Sloan Kettering Cancer Center; the University of Texas MD Anderson Cancer Center; the University of Rochester Medical Center; and Flatiron Health, Inc. The company has a strategic alliance with SOPHiA GENETICS SA for the development of liquid biopsy companion diagnostic (CDx) test. The co

Piotroski VR‑10 (Strict, 0-10) 3.0

Net Income: -365.9m TTM > 0 and > 6% of Revenue
FCF/TA: -0.02 > 0.02 and ΔFCF/TA 1.44 > 1.0
NWC/Revenue: 24.11% < 20% (prev 15.99%; Δ 8.13% < -1%)
CFO/TA 0.00 > 3% & CFO 1.80m > Net Income -365.9m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 2.49 > 1.5 & < 3
Outstanding Shares: last quarter (93.3m) vs 12m ago 2.41% < -2%
Gross Margin: 69.93% > 18% (prev 0.70%; Δ 6923 % > 0.5%)
Asset Turnover: 95.09% > 50% (prev 81.51%; Δ 13.58% > 0%)
Interest Coverage Ratio: -36.63 > 6 (EBITDA TTM -399.0m / Interest Expense TTM 10.5m)

Altman Z'' -9.79

A: 0.28 (Total Current Assets 332.6m - Total Current Liabilities 133.8m) / Total Assets 706.6m
B: -1.59 (Retained Earnings -1.12b / Total Assets 706.6m)
C: -0.44 (EBIT TTM -384.6m / Avg Total Assets 867.1m)
D: -3.31 (Book Value of Equity -1.12b / Total Liabilities 338.6m)
Altman-Z'' Score: -9.79 = D

Beneish M -3.87

DSRI: 0.97 (Receivables 115.3m/121.2m, Revenue 824.5m/837.6m)
GMI: 1.00 (GM 69.93% / 69.89%)
AQI: 0.55 (AQ_t 0.30 / AQ_t-1 0.54)
SGI: 0.98 (Revenue 824.5m / 837.6m)
TATA: -0.52 (NI -365.9m - CFO 1.80m) / TA 706.6m)
Beneish M-Score: -3.87 (Cap -4..+1) = AAA

What is the price of MYGN shares?

As of February 28, 2026, the stock is trading at USD 4.61 with a total of 2,127,021 shares traded.
Over the past week, the price has changed by +7.46%, over one month by -22.13%, over three months by -39.58% and over the past year by -58.32%.

Is MYGN a buy, sell or hold?

Myriad Genetics has received a consensus analysts rating of 3.33. Therefor, it is recommend to hold MYGN.

StrongBuy: 3
Buy: 3
Hold: 6
Sell: 2
StrongSell: 1

What are the forecasts/targets for the MYGN price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	7.8	68.8%
Analysts Target Price	7.8	68.8%

MYGN Fundamental Data Overview February 27, 2026

P/E Forward = 46.0829
P/S = 0.5404
P/B = 1.1952
P/EG = 1.4001
Revenue TTM = 824.5m USD
EBIT TTM = -384.6m USD
EBITDA TTM = -399.0m USD
Long Term Debt = 119.5m USD (from longTermDebt, two quarters ago)
Short Term Debt = 6.90m USD (from shortTermDebt, last quarter)
Debt = 209.8m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 60.2m USD (from netDebt column, last quarter)
Enterprise Value = 505.8m USD (445.6m + Debt 209.8m - CCE 149.6m)
Interest Coverage Ratio = -36.63 (Ebit TTM -384.6m / Interest Expense TTM 10.5m)
EV/FCF = -31.22x (Enterprise Value 505.8m / FCF TTM -16.2m)
FCF Yield = -3.20% (FCF TTM -16.2m / Enterprise Value 505.8m)
FCF Margin = -1.96% (FCF TTM -16.2m / Revenue TTM 824.5m)
Net Margin = -44.38% (Net Income TTM -365.9m / Revenue TTM 824.5m)
Gross Margin = 69.93% ((Revenue TTM 824.5m - Cost of Revenue TTM 247.9m) / Revenue TTM)
Gross Margin QoQ = 69.97% (prev 69.91%)
Tobins Q-Ratio = 0.72 (Enterprise Value 505.8m / Total Assets 706.6m)
Interest Expense / Debt = 2.10% (Interest Expense 4.40m / Debt 209.8m)
Taxrate = 21.0% (US default 21%)
NOPAT = -303.8m (EBIT -384.6m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 2.49 (Total Current Assets 332.6m / Total Current Liabilities 133.8m)
Debt / Equity = 0.57 (Debt 209.8m / totalStockholderEquity, last quarter 368.0m)
Debt / EBITDA = -0.15 (negative EBITDA) (Net Debt 60.2m / EBITDA -399.0m)
Debt / FCF = -3.72 (negative FCF - burning cash) (Net Debt 60.2m / FCF TTM -16.2m)
Total Stockholder Equity = 458.4m (last 4 quarters mean from totalStockholderEquity)
RoA = -42.20% (Net Income -365.9m / Total Assets 706.6m)
RoE = -79.81% (Net Income TTM -365.9m / Total Stockholder Equity 458.4m)
RoCE = -66.55% (EBIT -384.6m / Capital Employed (Equity 458.4m + L.T.Debt 119.5m))
RoIC = -53.49% (negative operating profit) (NOPAT -303.8m / Invested Capital 568.0m)
WACC = 8.79% (E(445.6m)/V(655.4m) * Re(12.15%) + D(209.8m)/V(655.4m) * Rd(2.10%) * (1-Tc(0.21)))
Discount Rate = 12.15% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 4.10%
[DCF] Fair Price = unknown (Cash Flow -16.2m)
EPS Correlation: 17.96 | EPS CAGR: 6.37% | SUE: 0.48 | # QB: 0
Revenue Correlation: 86.22 | Revenue CAGR: 6.63% | SUE: 0.36 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.06 | Chg7d=-0.063 | Chg30d=-0.062 | Revisions Net=+2 | Analysts=11
EPS current Year (2026-12-31): EPS=0.06 | Chg7d=-0.005 | Chg30d=-0.003 | Revisions Net=+1 | Growth EPS=+4.2% | Growth Revenue=+5.1%
EPS next Year (2027-12-31): EPS=0.17 | Chg7d=+0.025 | Chg30d=+0.025 | Revisions Net=+2 | Growth EPS=+164.5% | Growth Revenue=+5.6%
[Analyst] Revisions Ratio: +1.00 (2 Up / 0 Down within 30d for Next Quarter)

Additional Sources for MYGN Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Fund Manager Positions: Dataroma | Stockcircle